

Press release

Lund June 21st, 2022

Scandinavian ChemoTech hires investor relations consultant

Scandinavian ChemoTech AB (publ) has hired Jonathan Furelid as an investor relations consultant in order to strengthen the company's communication with its stakeholders.

Scandinavian Chemotech has hired Jonathan Furelid as an investor relations (IR) consultant with responsibility for the Company's communication with the stock market. Jonathan has over 20 years of experience from roles within the financial sector, which include risk analysis, portfolio management, financial communication and investor relations.

Jonathan will work with ChemoTech's communications from both a regulatory and strategic perspective, in order to broaden the knowledge of the Company and increase the understanding of its operations.

Jonathan takes on the consulting role of IR manager with immediate effect.

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se